GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tango Therapeutics Inc (NAS:TNGX) » Definitions » EV-to-EBIT

TNGX (Tango Therapeutics) EV-to-EBIT : -3.80 (As of Jul. 23, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Tango Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tango Therapeutics's Enterprise Value is $554.05 Mil. Tango Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-145.87 Mil. Therefore, Tango Therapeutics's EV-to-EBIT for today is -3.80.

The historical rank and industry rank for Tango Therapeutics's EV-to-EBIT or its related term are showing as below:

TNGX' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.92   Med: -3.15   Max: 1.25
Current: -3.8

During the past 5 years, the highest EV-to-EBIT of Tango Therapeutics was 1.25. The lowest was -28.92. And the median was -3.15.

TNGX's EV-to-EBIT is ranked worse than
100% of 430 companies
in the Biotechnology industry
Industry Median: 12.565 vs TNGX: -3.80

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Tango Therapeutics's Enterprise Value for the quarter that ended in Mar. 2025 was $-31.67 Mil. Tango Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-145.87 Mil. Tango Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 460.59%.


Tango Therapeutics EV-to-EBIT Historical Data

The historical data trend for Tango Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tango Therapeutics EV-to-EBIT Chart

Tango Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
- -8.16 -2.83 -6.25 -0.77

Tango Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.30 -4.79 -4.09 -0.77 0.22

Competitive Comparison of Tango Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Tango Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tango Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tango Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tango Therapeutics's EV-to-EBIT falls into.


;
;

Tango Therapeutics EV-to-EBIT Calculation

Tango Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=554.051/-145.87
=-3.80

Tango Therapeutics's current Enterprise Value is $554.05 Mil.
Tango Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-145.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tango Therapeutics  (NAS:TNGX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Tango Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=-145.87/-31.67004
=460.59 %

Tango Therapeutics's Enterprise Value for the quarter that ended in Mar. 2025 was $-31.67 Mil.
Tango Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-145.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tango Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Tango Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Tango Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
201 Brookline Avenue, Suite 901, Boston, MA, USA, 02215
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Executives
Douglas Barry officer: See Remarks TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Adam Crystal officer: See Remarks C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Barbara Weber director, officer: Chief Executive Officer C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Daniella Beckman officer: Chief Financial Officer C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Mace Rothenberg director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Third Rock Ventures Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Mva Investors, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Lesley Ann Calhoun director C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
John B Ketchum director TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Trv Gp Vi, Llc director 201 BROOKLINE AVE., BOSTON MA 02215
Third Rock Ventures Gp Vi, L.p. director 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Vi, L.p. director 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116